Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 6, 03 August 2023
Open
Access | Article
Eribulin and its application as anti-cancer treatment
* Author to whom correspondence should be addressed.
Abstract
Eribulin (E7389) is a synthetic small molecule medication with high anti-cancer efficacy exhibited in preclinical studies. It is a structure-simplified macrocyclic ketone analog of Halichondrin B, which can inhibit the development of microtubule that is essential for the mitosis of cancer cells. The U.S. Food and Drug Administration (FDA) has given eribulin approval as a third-line chemotherapy for patients with metastatic breast cancer (approved in 2010) or metastatic liposarcoma (approved in 2016). In a number of clinical trials, eribulin has shown outstanding efficacy and safety in the treatment of solid tumors, particularly for breast cancer and sarcoma. Current eribulin clinical trials focus on its use in the therapy of other various cancer types, including non-small cell lung cancer (NSCLC), salivary gland cancer, cervical cancer, urethral cancer, and prostate cancer, and its application in combination treatment. The present study summarizes the mechanism, development, and future directions of eribulin, with an emphasis on the results of clinical trials.
Keywords
eribulin, microtubule inhibitor, breast cancer, liposarcoma
References
1. Hirata, Y. and Uemura, D., “Halichondrins - antitumor polyether macrolides from a marine sponge,” Pure Appl. Chem. 58(5), 701–710 (1986).
2. Fodstad, Breistøl, K., Pettit, G., Shoemaker, R. H. and Boyd, M. R., “Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts,” J. Exp. Ther. Oncol. 1(2), 119–125 (1996).
3. Towle, M. J., Salvato, K. A., Budrow, J., Wels, B. F., Kuznetsov, G., Aalfs, K. K., Welsh, S., Zheng, W., Seletsky, B. M., Palme, M. H., Habgood, G. J., Singer, L. A., DiPietro, L. V., Wang, Y., Chen, J. J., Quincy, D. A., Davis, A., Yoshimatsu, K., Kishi, Y., et al., “In Vitro and In Vivo Anticancer Activities of Synthetic Macrocyclic Ketone Analogues of Halichondrin B1,” Cancer Res. 61(3), 1013–1021 (2001).
4. Austad, B. C., Calkins, T. L., Chase, C. E., Fang, F. G., Horstmann, T. E., Hu, Y., Lewis, B. M., Niu, X., Noland, T. A., Orr, J. D., Schnaderbeck, M. J., Zhang, H., Asakawa, N., Asai, N., Chiba, H., Hasebe, T., Hoshino, Y., Ishizuka, H., Kajima, T., et al., “Commercial manufacture of halaven®: Chemoselective transformations en route to structurally complex macrocyclic ketones,” Synlett 24(3), 333–337 (2013)
5. Jordan, M. A. and Wilson, L., “Microtubules as a target for anticancer drugs,” 4, Nat. Rev. Cancer 4(4), 253–265 (2004).
6. Bai, R., Nguyen, T. L., Burnett, J. C., Atasoylu, O., Munro, M. H. G., Pettit, G. R., Smith, A. B. I., Gussio, R. and Hamel, E., “Interactions of Halichondrin B and Eribulin with Tubulin,” J. Chem. Inf. Model. 51(6), 1393–1404 (2011).
7. Smith, J. A., Wilson, L., Azarenko, O., Zhu, X., Lewis, B. M., Littlefield, B. A. and Jordan, M. A., “Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability,” Biochemistry 49(6), 1331–1337 (2010).
8. Jordan, M. A., Kamath, K., Manna, T., Okouneva, T., Miller, H. P., Davis, C., Littlefield, B. A. and Wilson, L., “The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth,” Mol. Cancer Ther. 4(7), 1086–1095 (2005).
9. Morris, P. G., “Advances in therapy: eribulin improves survival for metastatic breast cancer,” Anticancer. Drugs 21(10), 885–889 (2010).
10. Synold, T. W., Morgan, R. J., Newman, E. M., Lenz, H. J., Gandara, D. R., Colevas, A. D., Lewis, M. D. and Doroshow, J. H., “A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial,” J. Clin. Oncol. 23(16_suppl), 3036–3036 (2005).
11. Tan, A. R., Rubin, E. H., Walton, D. C., Shuster, D. E., Wong, Y. N., Fang, F., Ashworth, S. and Rosen, L. S., “Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors,” Clin. Cancer Res. 15(12), 4213–4219 (2009).
12. Goel, S., Mita, A. C., Mita, M., Rowinsky, E. K., Chu, Q. S., Wong, N., Desjardins, C., Fang, F., Jansen, M., Shuster, D. E., Mani, S. and Takimoto, C. H., “A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies,” Clin. Cancer Res. 15(12), 4207–4212 (2009).
13. Markman, M., “Management of toxicities associated with the administration of taxanes,” Expert Opin. Drug Saf. 2(2), 141–146 (2003).
14. Lheureux, S., Oza, A. M., Laurie, S. A., Halford, R., Jonker, D., Chen, E., Keller, D., Bourade, V., Wang, L., Doyle, L., Siu, L. L. and Goel, R., “A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium,” 11, Br. J. Cancer 113(11), 1534–1540 (2015).
15. Marmé, F., Gomez-Roca, C., Graudenz, K., Huang, F., Lettieri, J., Peña, C., Trnkova, Z. J. and Eucker, J., “Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors,” Cancer Chemother. Pharmacol. 81(4), 727–737 (2018).
16. Vahdat, L. T., Pruitt, B., Fabian, C. J., Rivera, R. R., Smith, D. A., Tan-Chiu, E., Wright, J., Tan, A. R., DaCosta, N. A., Chuang, E., Smith, J., O’Shaughnessy, J., Shuster, D. E., Meneses, N. L., Chandrawansa, K., Fang, F., Cole, P. E., Ashworth, S. and Blum, J. L., “Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane,” J. Clin. Oncol. 27(18), 2954–2961 (2009).
17. Cortes, J., Vahdat, L., Blum, J. L., Twelves, C., Campone, M., Roché, H., Bachelot, T., Awada, A., Paridaens, R., Goncalves, A., Shuster, D. E., Wanders, J., Fang, F., Gurnani, R., Richmond, E., Cole, P. E., Ashworth, S. and Allison, M. A., “Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine,” J. Clin. Oncol. 28(25), 3922–3928 (2010).
18. Schöffski, P., Ray-Coquard, I. L., Cioffi, A., Bui, N. B., Bauer, S., Hartmann, J. T., Krarup-Hansen, A., Grünwald, V., Sciot, R., Dumez, H., Blay, J.-Y., Cesne, A. L., Wanders, J., Hayward, C., Marreaud, S., Ouali, M. and Hohenberger, P., “Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes,” Lancet Oncol. 12(11), 1045–1052 (2011).
19. Kawai, A., Araki, N., Naito, Y., Ozaki, T., Sugiura, H., Yazawa, Y., Morioka, H., Matsumine, A., Saito, K., Asami, S. and Isu, K., “Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†,” Jpn. J. Clin. Oncol. 47(2), 137–144 (2017).
20. Gitlitz, B. J., Tsao-Wei, D. D., Groshen, S., Davies, A., Koczywas, M., Belani, C. P., Argiris, A., Ramalingam, S., Vokes, E. E., Edelman, M., Hoffman, P., Ballas, M. S., Liu, S. V. and Gandara, D. R., “A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial,” J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 7(3), 574–578 (2012).
21. Stein, M. N., Chen, Y.-H., Carducci, M. A., Hudes, G. R., Lerma, P. M., Tan, W. W., Dalune, R., Rowland, K. M., Kuzel, T. M. and DiPaola, R. S., “Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805),” Am. J. Clin. Oncol. 42(4), 375–381 (2019).
22. Isakoff, M. S., Goldsby, R., Villaluna, D., Krailo, M. D., Hingorani, P., Collier, A., Morris, C. D., Kolb, E. A., Doski, J. J., Womer, R. B., Gorlick, R. and Janeway, K. A., “A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children’s Oncology Group,” Pediatr. Blood Cancer 66(2), e27524 (2019).
23. Rodriguez, C. P., Martins, R. G., Baik, C., Chow, L. Q., Santana-Davila, R., Goulart, B. H., Lee, S. and Eaton, K. D., “Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies,” Head Neck 40(3), 584–589 (2018).
24. Smith, J. W., Vukelja, S., Hoffman, A. D., Jones, V. E., McIntyre, K., Berrak, E., Song, J. X. and O’Shaughnessy, J., “Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer,” Clin. Breast Cancer 16(1), 31–37 (2016).
25. Vahdat, L. T., Garcia, A. A., Vogel, C., Pellegrino, C., Lindquist, D. L., Iannotti, N., Gopalakrishna, P. and Sparano, J. A., “Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy,” Breast Cancer Res. Treat. 140(2), 341–351 (2013).
26. Yonemori, K., Shimomura, A., Yasojima, H., Masuda, N., Aogi, K., Takahashi, M., Naito, Y., Shimizu, S., Nakamura, R., Hashimoto, J., Yamamoto, H., Hirakawa, A., Michimae, H., Hamada, A., Yoshida, T., Sukigara, T., Tamura, K. and Fujiwara, Y., “A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes,” Eur. J. Cancer Oxf. Engl. 1990 109, 84–91 (2019).
27. Cortes, J., O’Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., Vladimirov, V., Cardoso, F., Koh, H., Bougnoux, P., Dutcus, C. E., Seegobin, S., Mir, D., Meneses, N., Wanders, J., et al., “Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study,” The Lancet 377(9769), 914–923 (2011).
28. Kaufman, P., Awada, A., Twelves, C., Yelle, L., Perez, E., Wanders, J., Olivo, M., He, Y. and Dutcus, C., “Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes,” Cancer Res. 72(24_Supplement), S6-6 (2012).
29. Twelves, C., Cortes, J., Vahdat, L., Olivo, M., He, Y., Kaufman, P. A. and Awada, A., “Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies,” Breast Cancer Res. Treat. 148(3), 553–561 (2014).
30. Demetri, G. D., Schöffski, P., Grignani, G., Blay, J.-Y., Maki, R. G., Van Tine, B. A., Alcindor, T., Jones, R. L., D’Adamo, D. R., Guo, M. and Chawla, S., “Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine,” J. Clin. Oncol. 35(30), 3433–3439 (2017).
31. FUJII, T., TOKUDA, S., NAKAZAWA, Y., KUROZUMI, S., OBAYASHI, S., YAJIMA, R. and SHIRABE, K., “Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer,” In Vivo 34(2), 917–921 (2020).
32. Mougalian, S. S., Kish, J. K., Zhang, J., Liassou, D. and Feinberg, B. A., “Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States,” Adv. Ther. 38(5), 2213–2225 (2021).
33. “Home - ClinicalTrials.gov.”, <https://clinicaltrials.gov/> (18 December 2022 ).
34. Katakami, N., Felip, E., Spigel, D. R., Kim, J.-H., Olivo, M., Guo, M., Nokihara, H., Yang, J. C.-H., Iannotti, N., Satouchi, M. and Barlesi, F., “A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer,” Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28(9), 2241–2247 (2017).
35. La Verde, N., Damia, G., Garrone, O., Santini, D., Fabi, A., Ciccarese, M., Generali, D. G., Nunzi, M., Poletto, E., Ferraris, E., Cretella, E., Scandurra, G., Meattini, I., Bertolini, A. S., Cavanna, L., Collovà, E., Romagnoli, E., Rulli, E., Legramandi, L., et al., “Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study,” Breast Cancer Res. 24(1), 71 (2022).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
- ISBN (Print)
- 978-1-915371-65-2
- ISBN (Online)
- 978-1-915371-66-9
- Published Date
- 03 August 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/6/20230176
- Copyright
- 03 August 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited